ReviewEuropean heart journal2021
Colchicine and the heart.
Review in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 5 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Cardiovascular Benefit and Gastrointestinal Risk of Colchicine in Secondary Prevention: Risk Associated with Dose and Treatment Duration.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Pooled it
- Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Pooled it
- Efficacy and safety of colchicine post myocardial infarction: a systematic review, meta-analysis and meta-regression analysis of randomized clinical trials.European journal of clinical pharmacology · 2025Pooled it
- Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025Pooled it
- Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging.JACC. Cardiovascular imaging · 2024Guideline
- Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-controlled Trial.Reviews on recent clinical trials · 2025Trial
- Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.Immunological reviews · 2026Review
- Review
- Colchicine enhances macrophage cholesterol efflux by targeting DTL-mediated ubiquitination and degradation of ABCA1.RMD open · 2026Article
- Article
- Review
- Cardiac-homing peptide-targeted colchicine-based drugstores with inhibiting inflammatory response for myocardial infarction improvement.Materials today. Bio · 2026Article
- Pericardial Effusion After Cardiac Surgery: Prevalence, Characteristics, Risk Factors and Management.Journal of clinical medicine · 2026Article
- Therapeutic perspective on cardiomyopathy and heart failure in older adults through the lens of chronic inflammation.Vascular pharmacology · 2026Article
- Gut-heart axis disruption and LPS translocation: driving atrial fibrillation through inflammatory storm and fibrotic mechanisms.Frontiers in endocrinology · 2026Review
- Colchicine for Prevention of Recurrent Stroke-Are we CONVINCED?Journal of the American Heart Association · 2025Article
- Microalgae-based hydrogel drug delivery system for treatment of gouty arthritis with alleviated colchicine side effects.Bioactive materials · 2025Article
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- Impact of Colchicine Therapy on Ventriculoarterial Coupling in Familial Mediterranean Fever: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Colchicine and Atherosclerotic Coronary Artery Disease: An Updated Review.Journal of clinical medicine · 2025Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colchicine is a unique, sophisticated anti-inflammatory agent that has been used for decades for the prevention of acute inflammatory flares in gout and familial Mediterranean fever. In recent years, clinical trials have demonstrated its potential in a range of cardiovascular (CV) conditions. Colchicine is avidly taken up by leucocytes, and its ability to bind to tubulin and interfere with microtubular function affects the expression of cytokines and interleukins, and the ability of neutrophils to marginate, ingress, aggregate, express superoxide, release neutrophil extracellular traps, and interact with platelets. In patients with acute and recurrent pericarditis, clinical trials in >1600 patients have consistently shown that colchicine halves the risk of recurrence [relative risk (RR) 0.50, 95% confidence interval (CI) 0.42-0.60]. In patients with acute and chronic coronary syndromes, multicentre randomized controlled trials in >11 000 patients followed for up to 5 years demonstrated that colchicine may reduce the risk of CV death, myocardial infarction, ischaemic stroke and ischaemia-driven revascularization by >30% (RR 0.63, 95% CI 0.49-0.81). The use of colchicine at doses of 0.5-1.0 mg daily in CV trials has proved safe. Early gastrointestinal intolerance limits its use in ∼10% of patients; however, ∼90% of patients tolerate it well over the long term. Despite isolated case reports, clinically relevant drug interactions with moderate to strong CYP3A4 inhibitors/competitors or P-glycoprotein inhibitors/competitors are rare if this dosage of colchicine is used in the absence of advanced renal or liver disease. The aim of this review is to summarize the contemporary data supporting the efficacy and safety of colchicine in patients with CV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.